Equities

Poolbeg Pharma PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Poolbeg Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)4.87
  • Today's Change0.165 / 3.51%
  • Shares traded967.27k
  • 1 Year change+1.35%
  • Beta2.0687
Data delayed at least 20 minutes, as of Feb 20 2026 15:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 15-Jan-26
  • 19-Feb-26
Select bar for recommendation details.
Recommendations19-Feb-26
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in GBX

The one analyst offering a 12 month price target expects Poolbeg Pharma PLC share price to rise to 19.00 in the next year from the last price of 4.70.
High304.3%19.00
Med304.3%19.00
Low304.3%19.00

Earnings history & estimates in GBX

Poolbeg Pharma PLC reported annual 2024 losses of -1.16 per share on May 20, 2025.
Average growth rate-15.44%
More ▼

Revenue history & estimates in GBP

Poolbeg Pharma PLC did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.